Welcome to our dedicated page for SRNG news (Ticker: SRNG), a resource for investors and traders seeking the latest updates and insights on SRNG stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SRNG's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SRNG's position in the market.
Ginkgo Bioworks has announced a partnership with Huue to enhance sustainable dye production. Leveraging Ginkgo's microbial engineering platform, Huue aims to optimize microbe strains for efficient production of indigo dye, significantly reducing environmental impact. The partnership is part of Ginkgo's broader mission to apply synthetic biology across various industries, addressing pressing environmental challenges. Ginkgo's business combination with Soaring Eagle Acquisition Corp. (SRNG) is anticipated to finalize in Q3 2021, enhancing Ginkgo’s growth prospects in the biotech sector.
Ginkgo Bioworks has reported a significant surge in revenue for the first half of 2021, totaling $88 million, a 180% increase from the previous year. The company noted strong performance across its Foundry and Biosecurity sectors, with both sectors generating $44 million each. Ginkgo's business combination with Soaring Eagle Acquisition Corp. (SRNG) is expected to finalize shortly after a shareholder meeting on September 14, 2021, potentially providing up to $2.5 billion in gross cash proceeds. Ginkgo is also set to enhance its biosecurity services amid rising COVID-19 concerns.
Antheia and Ginkgo Bioworks announced a partnership to enhance the development and production of essential medicines using synthetic biology. This collaboration aims to accelerate the creation of active pharmaceutical ingredients and key starting materials by leveraging Ginkgo's advanced enzyme design capabilities. The partnership seeks to address the fragility of supply chains for plant-based medicines, which can lead to shortages during times of high demand, such as the COVID-19 pandemic. The goal is to improve the efficiency and sustainability of producing critical medicines.
Ginkgo Bioworks and Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) announced the SEC's approval of their Form S-4 registration, a crucial step towards their business combination. This merger is slated for Q3 2021, allowing Ginkgo to trade publicly under the ticker "DNA." The transaction could yield gross cash proceeds of up to $2.5 billion, including $1.725 billion from Soaring Eagle's trust and $775 million from a PIPE transaction. Ginkgo aims to simplify biotechnology, impacting various sectors like food and pharmaceuticals.
Aldevron and Ginkgo Bioworks announced a significant manufacturing breakthrough focused on the vaccinia capping enzyme (VCE), which is critical for mRNA vaccine production. This partnership has resulted in a new process that improves manufacturing yield by over ten times compared to previous methods. Aldevron has secured exclusive rights to this process, enhancing its portfolio while positioning Ginkgo to expand its pharmaceutical capabilities. The collaboration is set against the backdrop of Ginkgo's planned business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), expected to close in Q3 2021.
Ginkgo Bioworks announced a presentation to review its first half 2021 results on August 18, 2021, at 4:30 p.m. ET, following its business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG). The presentation will cover performance, updates, and the company's business outlook. Registration details will be available on Ginkgo's investor relations website, with a replay to follow. Ginkgo is focused on programming cells for diverse biotechnology applications and is involved in COVID-19 response efforts. The merger is anticipated to close in Q3 2021, pending approvals.
Bolt Threads and Ginkgo Bioworks announced a partnership to enhance the production of b-silk protein. This collaboration aims to leverage Ginkgo's strain engineering expertise to improve sustainability and efficiency in manufacturing, potentially scaling b-silk for wider use in clean beauty products. Bolt Threads, noted for its innovative materials, has proven b-silk's effectiveness in personal care applications. Ginkgo is also in the process of merging with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), anticipated to close in Q3 2021, further expanding its biotechnology applications.
On August 3, 2021, Ginkgo Bioworks announced that Dr. Reshma Kewalramani, CEO of Vertex, will join its board of directors. This addition comes after Ginkgo's planned business combination with Soaring Eagle Acquisition Corp. (Nasdaq:SRNG). Dr. Kewalramani has significant experience in drug development and has been pivotal in advancing therapies for cystic fibrosis. Her expertise is expected to enhance Ginkgo's capabilities, especially in pharmaceuticals. The board will expand to eight members following the transaction's completion, expected in Q3 2021, pending approvals.
BOSTON, July 29, 2021 /PRNewswire/ -- Ginkgo Bioworks announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG). The company is set to participate in two key conferences: the Jefferies Virtual Industrials Conference on August 4, 2021, at 10:30 a.m. ET, and the UBS Genomics 2.0 and Medtech Innovations Summit on August 11, 2021, at 1:00 p.m. ET. Live webcasts of these events will be available on Ginkgo's investor relations website.
Ginkgo Bioworks will host a virtual Investor Day on June 24, 2021, starting at 1:00 PM ET. This event will include discussions with Ginkgo's founders, a virtual tour, and presentations by senior management. Registration details are available on their investor website. Ginkgo, in partnership with Soaring Eagle Acquisition Corp (SRNG), aims to finalize a proposed merger by Q3 2021. Additionally, Ginkgo will participate in several investor conferences, including the UBS Global Healthcare Conference on May 26 and the Jefferies Healthcare Conference on June 1.
